This article is more than 5 years old. Information may no longer be current.

BioStructures announces FDA approval for bone graft solution

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BioStructures recently announced they have received FDA clearance for their new Silhouette MCS Bone Graft.

Indicated for better biologic responsiveness at the defect site and enhanced handling during the procedure, Silhouette is made of a bi-phasic mineral component within multiple type I collagen fibers. The company touts the graft allows for improved introduction of autogenic bone marrow aspirate, allowing for improved healing.

"We are very pleased to receive FDA clearance for Silhouette Mineralized Collagen Scaffold,” Russell Cook, chief executive officer of BioStructures, stated in a company release. “We founded BioStructures in 2009 with the goal to develop and commercialize proprietary first-in-class products in the bioactive, polymer, collagen and cellular bone graft spaces. The Silhouette clearance represents the third step in our attainment of that goal.”

“Looking forward, we will continue to develop our pipeline of products in a continued effort to offer a unique breadth of products all under the BioStructures umbrella."

Reference: www.biostructures.net